Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 30 December 2025 - 31 December 2025

Salesforce stock (CRM) slips after-hours as year-end tech trade cools and Fed minutes bite

Salesforce stock (CRM) slips after-hours as year-end tech trade cools and Fed minutes bite

NEW YORK, December 30, 2025, 18:23 ET — After-hours Salesforce (CRM) shares slipped 0.1% in after-hours trading on Tuesday to $265.92. The stock opened at $266.66 and traded between $265.38 and $268.21 during the regular session, with volume around 3.3 million shares. The late-day drift matters because year-end trading is thin, and small orders can move large-cap software names more than usual. With 2026 positioning under way, investors are quick to trim risk when the tape softens. Salesforce sits at the intersection of two themes that have dominated markets into the close of 2025: interest-rate expectations and a race to
31 December 2025
·····
CoreWeave stock slips after-hours after insider sale filing; CRWV traders watch what comes next

CoreWeave stock slips after-hours after insider sale filing; CRWV traders watch what comes next

NEW YORK, December 30, 2025, 17:53 ET — After-hours CoreWeave shares fell 1.4% to $73.90 in regular trading on Tuesday and slipped 0.3% after the bell to $73.70. The stock move landed as investors weighed an insider sale disclosed in a regulatory filing, a headline that can carry extra weight in holiday-thin markets when volumes are light and price swings can widen. SEC CoreWeave has become a closely watched proxy for artificial-intelligence infrastructure spending, and traders remain quick to react to signs of added share supply or shifts in sentiment around capital intensity. In a Form 4 filed on Monday,
31 December 2025
····
Coinbase stock dips after-hours as Needham slashes target, flags weak crypto volumes

Coinbase stock dips after-hours as Needham slashes target, flags weak crypto volumes

NEW YORK, December 30, 2025, 17:20 ET — After-hours Coinbase Global shares slipped in after-hours trading on Tuesday after Needham lowered its price target on the crypto exchange operator, pointing to a weaker outlook for trading activity. TipRanks The call matters because Coinbase’s results are closely tied to trading volumes — the amount of buying and selling on its platforms — which can cool when price momentum fades and retail investors step back. TipRanks That dynamic is back in focus heading into year-end, when liquidity thins and swings in crypto-linked stocks can be amplified by small shifts in risk appetite.
30 December 2025
·····
GOOG stock steady after hours: Google’s Gemini 3 Flash push and what traders watch next

GOOG stock steady after hours: Google’s Gemini 3 Flash push and what traders watch next

NEW YORK, December 30, 2025, 16:33 ET — After-hours Alphabet Inc’s Class C shares (GOOG), which carry no voting rights, were up 0.1% at $314.55 in after-hours trading on Tuesday, after the regular U.S. session ended at 4 p.m. ET. The stock’s muted move comes as investors parse how quickly Google can translate fresh AI product rollouts into revenue growth, without letting data-center costs run away. Google laid out a late-December roundup of those AI updates on its company blog, and its Search team said a broad ranking change has finished rolling out. blog.google+1 Year-end positioning has also kept trading
30 December 2025
····
Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade

Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade

NEW YORK, December 30, 2025, 15:41 ET — Regular session Qualys Inc shares fell 2.5% to $133.93 in afternoon trading on Tuesday, after dropping as much as 4.2% earlier in the session. The stock closed at $137.34 on Monday. The decline landed as U.S. equities stayed range-bound in holiday-thin conditions, with technology and financial shares among the drags. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters That matters for Qualys because lighter year-end liquidity can exaggerate moves in single names, especially in software stocks where
30 December 2025
·····
SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

NEW YORK, December 30, 2025, 15:25 ET — Regular session Scholar Rock Holding Corp (SRRK) slid 3.2% to $43.76 in afternoon trading on Tuesday after opening at $45.18. The stock traded between $45.95 and $43.74. The move matters because Scholar Rock’s near-term valuation still hinges on regulatory timing for apitegromab, its lead drug candidate. he company said in an October update that the FDA classified a third-party manufacturing site in Bloomington, Indiana (formerly Catalent Indiana LLC, now fully owned and operated by Novo Nordisk) as “official action indicated” and that it requested a Type A meeting to discuss resubmitting its
30 December 2025
·····
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

NEW YORK, December 30, 2025, 15:16 ET — Regular session Travere Therapeutics Inc shares were down about 3.8% at $37.39 on Tuesday afternoon, extending losses after recent insider-trading disclosures. The stock traded between $37.27 and $39.20, with about 893,000 shares changing hands. (TVTX quote) The selling matters because it lands just weeks before a major regulatory milestone for the rare-disease drugmaker. Traders often react to clusters of insider sales — even when they are planned — as they reassess near-term positioning. Travere, based in San Diego, markets Filspari for a kidney disease called IgA nephropathy, and is seeking an expansion
30 December 2025
·····
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

NEW YORK, December 30, 2025, 14:54 ET — Regular session Shares of Praxis Precision Medicines Inc (NASDAQ: PRAX) slipped about 3% on Tuesday, giving back part of a sharp rally sparked by an FDA regulatory boost for its lead essential tremor program. The stock was down 3% at $295.50 as of 2:39 p.m. ET, after opening at $304.00 and trading between $286.58 and $304.70. The company said on Monday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ulixacaltamide to treat essential tremor, and said the decision was based on positive topline results from the Essential3 program, two
30 December 2025
·····
Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

NEW YORK, December 30, 2025, 14:50 ET — Regular session Shares of lululemon athletica inc. fell about 0.6% to $211.30 in afternoon trading on Tuesday after founder Chip Wilson launched a proxy fight — a campaign to win shareholder votes for board seats — seeking to reshape the board. The stock had gained about 2% on Monday, Reuters reported. Reuters The board fight comes as the athletic apparel maker searches for a permanent chief executive after Calvin McDonald said he would step down on Jan. 31. Chief financial officer Meghan Frank and chief commercial officer André Maestrini are set to
30 December 2025
·····
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance An NDA is the formal request asking the FDA to review a drug for marketing approval, a key inflection point for development-stage biotechs with no products on the market. U.S. Food and Drug Administration Systemic mastocytosis is a rare disorder marked by abnormal accumulation and activation of mast cells — immune
30 December 2025
·····
Schwab stock slips as Fed minutes put rate outlook back in focus

Schwab stock slips as Fed minutes put rate outlook back in focus

NEW YORK, December 30, 2025, 14:00 ET — Regular session The Charles Schwab Corp’s shares were down 0.6% at $100.69 in afternoon trading on Tuesday, after opening at $101.58 and trading between $100.34 and $101.60. The broader market was little changed, while rivals Interactive Brokers and Robinhood also traded lower. The move matters because Schwab earns a large share of its revenue from client cash, making the stock sensitive to shifts in interest-rate expectations. That sensitivity can show up quickly on quiet days, when small changes in rate bets have an outsized impact on financial stocks. Investors are also looking
30 December 2025
·······
GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

NEW YORK, December 30, 2025, 1:54 PM ET — Regular session Genmab A/S’s U.S.-listed shares (GMAB) fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares changing hands. The move keeps attention on Genmab’s pipeline as investors reassess which late-stage assets can power growth. Dropping a late-stage program can change a biotech’s outlook quickly because those trials sit closest to potential approvals and revenue. Genmab said on Monday it will discontinue further clinical development of acasunlimab after a portfolio review, citing a more competitive landscape. “After
30 December 2025
·····
1 … 78 79 80 81 82 … 282

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Go toTop